SecProbe.io

CORRESP
1
filename1.htm

December 15, 2017

VIA EDGAR

Division of Corporation Finance

SECURITIES AND EXCHANGE COMMISSION

100 F Street, N.E.

Washington, DC 20549

Attention: Ms. Suzanne Hayes

    Re:
    Adial Pharmaceuticals, Inc.

    Registration Statement on Form S-1;

(SEC File No. 333-220368)

Dear Ms. Hayes:

Acting as representatives
to the several underwriters, we hereby join in the request of Adial Pharmaceuticals, Inc. that the effective date of the above-captioned
Registration Statement be accelerated so that it will become effective at 5:00 p.m., Eastern Time, on December 19, 2017, or as
soon thereafter as practicable.

Pursuant to Rule 460 of
the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended, we, acting
on behalf of the several underwriters, wish to advise you that, between November 24, 2017 and December 18, 2017, we distributed
to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security,
as many copies, as well as “E-red” copies of the Preliminary Prospectus dated November 22, 2017 as appears to be reasonable
to secure adequate distribution of the preliminary prospectus.

We confirm that we are
aware of our obligations under the Securities Act of 1933, as amended, and that we have and will comply with Rule 15c2-8 under
the Securities Exchange Act of 1934, as amended, with respect to the distribution of the Prospectus. We have been informed by the
other underwriters participating in the distribution of this offering that such persons have and will comply with Rule 15c2-8 with
respect to the distribution of the Prospectus.

    Very Truly Yours,

By: JOSEPH
GUNNAR & CO., LLC

    By:
    /s/ Eric Lord

    Name:
    Eric Lord

    Title:
    Head of Investment Banking/Underwritings

        Global Equity Capital Markets